ICCC vs. AWH, ABIO, OCX, CDIO, TRIB, BMRA, TKNO, VNRX, ACHV, and NAII
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Aspira Women's Health (AWH), ARCA biopharma (ABIO), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), VolitionRx (VNRX), Achieve Life Sciences (ACHV), and Natural Alternatives International (NAII). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are owned by institutional investors. 6.3% of ImmuCell shares are owned by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 29.55% of users gave Aspira Women's Health an outperform vote.
ImmuCell has a net margin of -33.05% compared to Aspira Women's Health's net margin of -176.74%. ImmuCell's return on equity of -21.79% beat Aspira Women's Health's return on equity.
In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 0.00 beat Aspira Women's Health's score of -0.31 indicating that ImmuCell is being referred to more favorably in the media.
ImmuCell has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Aspira Women's Health has a consensus target price of $4.45, suggesting a potential upside of 38.63%. Given Aspira Women's Health's higher possible upside, analysts clearly believe Aspira Women's Health is more favorable than ImmuCell.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 16 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
